Novo suffers regulatory setback in the US
Novo Nordisk has been delayed in its efforts to launch a new insulin product on the US market after the FDA sent a complete response letter to the company.
BY STEFAN SINGH KAILAY
Novo Nordisk said over the weekend that the company has received a complete response letter from the US FDA in relation to its application for faster-acting insulin aspart.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analyst: New Novo drug can defend huge business
For abonnenter
Novo launches new drug in Mexico
For abonnenter
